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fluorescent	 signal,	 likely	 due	 to	 the	 oxidation	 and	 bleaching	 of	 iLOV-	bound	 flavin	
mononucleotide.	We	 therefore	employed	an	anti-	iLOV	antibody	 for	 immunohisto-
chemical	and	immunofluorescence	imaging.	The	iLOV	signal	was	identified	in	airway	
epithelial	cells	and	CD45+	CD11b+	lung	macrophages.












RV	 is	 placed	 in	 the	 Picornaviridae	 family,	 genus	 Enterovirus,	
with	 three	 species	 based	 on	 phylogenetic	 sequence	 criteria.5,6 
Clinical	specimens	collected	from	in	the	1960s	and	1970s	yielded	
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studies	 have	 employed	 experimental	 infection	 with	 RV-	A16.9,10 
Mouse	 studies	 have	used	RV-	A1B	wild-	type	mice11	 or	RV-	A16	 in	
mice	 that	 are	 transgenic	 for	 human	 intercellular	 adhesion	 mole-
cule-	1.12	 These	models	 have	 been	 particularly	 useful	 in	 studying	
RV-	induced	exacerbations	of	allergic	airways	disease.	To	detect	RV	

























marker.26	RV1A-	iLOV	is	viable,	and	 its	expressed	 iLOV	protein	 is	
trackable	both	in	vitro	and	in	vivo,	suggesting	that	RV1A-	iLOV	may	
be	 a	 useful	 tool	 in	 the	 study	 of	 RV	 pathogenesis.	 However,	 the	
detection	of	iLOV-	expressing	RV	in	fixed	tissue	required	the	use	of	
an	anti-	iLOV	antibody,	limiting	the	value	of	this	construct.
2  | MATERIAL S AND METHODS
2.1 | Cells and reagents
H1-	Hela	and	THP-	1	cells	were	purchased	from	ATCC	(Manassas,	VA).	
Plasmids	 pEGFP-	N1	 (Clontech,	 Mountain	 View,	 CA),	 pRL	 (Renilla	
luciferase;	 Promega,	 Madison,	 WI),	 and	 pUC18-	ilOV	 (GenScript,	
Piscataway,	NJ)	were	used	to	amplify	the	DNA	fragments	of	green	
fluorescent	protein	(GFP),	Renilla	 luciferase	(RL),	and	iLOV,	respec-
tively.	 (For	 the	 detailed	 iLOV	 nucleotide	 sequence,	 see	 Table	 S1.)	
Antibody	 to	 RV	 VP2/VP0	 was	 obtained	 from	 QED	 Biosciences	
(San	Diego,	CA).	Anti-	GFP	Ab	was	purchased	 from	Thermo	Fisher	
Scientific	 (Waltham,	MA).	A	synthesized	peptide	fragment	of	 iLOV	
(CLGRNARFLQGPETD)	was	 generated	 and	 used	 to	 generate	 anti-	
iLOV	antibody	(GenScript).	Bafilomycin	was	purchased	from	Merck	
Millipore	(Burlington,	MA).
2.2 | Design and construction of recombinant 





were	 designed	 to	 be	 flanked	 by	 the	 edited	 nucleotide	 sequences	
encoding	 the	 viral	 2Apro	 cleavage	 site	with	 silent	mutations	 intro-







2.3 | Generation of recombinant RV





using	 Lipofectamine	 MessengerMAX	 (Thermo	 Fisher	 Scientific).	









assay28	 or	 quantitative	 one-	step	 real-	time	 polymerase	 chain	 re-
action	 for	 positive-	strand	 viral	 RNA	 using	 RV-	specific	 primers	
and	 probes	 (forward	 primer:	 5′-	GTGAAGAGCCSCRTGTGCT-	3′;	
reverse	 primer:	 5′-	GCTSCAGGGTTAAGGTTAGCC-	3′;	 probe:	 5′
-	FAM-	TGAGTCCTCCGGCCCCTGAATG-	TAMRA-	3′).29	 The	 limit	
of	 detection	 for	 this	 viral	 copy	 number	 analysis	 is	 between	 0	
and	 10	 copies.	 The	 presence	 of	 the	 GFP,	 RL,	 and	 iLOV	 inserts	
was	 determined	 using	 RV-	specific	 flanking	 primers	 (forward	
primer:	 5′-	CATTCTGTTGTCATCACAACACA-	3′;	 reverse	 primer:	
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2.5 | Animals and RV infection
Animal	 usage	 followed	 guidelines	 set	 forth	 in	 the	 Principles	 of	
Laboratory	 Animal	 Care	 from	 the	 National	 Society	 for	 Medical	
Research.	 Six-	day-	old	 or	 8-	 to	 10-	week-	old	 BALB/c	 mice	 (Jackson	
Laboratories,	 Bar	 Harbor,	ME)	were	 treated	 intranasally	with	 15	 or	
50	μL	of	108	plaque	forming	units	of	virus	and	harvested	24	hours	later.
2.6 | Histology, immunohistochemistry, and 
immunofluorescence microscop
For	histology,	mouse	 lungs	were	perfused	 through	 the	pulmonary	
artery	with	PBS	containing	5	mmol/L	EDTA	and	fixed	with	4%	para-
formaldehyde	overnight.	 For	 immunohistochemistry,	 lung	 sections	
were	stained	with	rabbit	anti-	iLOV,	then	incubated	with	biotinylated	
secondary	goat-	IgG,	ABC	reagent	(Vector	Laboratories,	Burlingame,	








2.7 | Quantitative real- time PCR of lung cytokines
Lung	 RNA	 was	 extracted	 with	 TRIzol	 Reagent	 (Thermo	 Fisher	
Scientific)	 combined	 with	 on-	column	 digestion	 of	 genomic	 DNA	
(QIAGEN,	Valencia,	CA).	cDNA	was	synthesized	from	1	μg	of	RNA	
and	 subjected	 to	 quantitative	 real-	time	 PCR	 using	 specific	mRNA	



















Data	 are	 represented	 as	 mean	 ±	 SE.	 Statistical	 significance	 was	
assessed	 using	 an	 unpaired	 t	 test	 or	 one-	way	 ANOVA,	 as	 appro-
priate.	 Group	 differences	 were	 pinpointed	 by	 a	 Tukey’s	 multiple-	
comparison	test.
3  | RESULTS









passages	 (P1-	P3).	A	 cytopathic	 effect	 (CPE)	was	observed	 in	HeLa	
cell-	infected	 RV1A-	GFP	 (Figure	1B).	 However,	 we	 were	 unable	









3.2 | Generation and characterization of RV1A- iLOV








By	 immunofluorescence,	 iLOV	 signal	 (green)	 appeared	 in	 RV1A-	
iLOV–infected	cells	only,	further	confirming	the	expression	of	iLOV	
(Figure	2C).	 Western	 blot	 analysis	 using	 rabbit	 sera	 recognizing	
the	iLOV	protein	showed	expression	of	a	product	of	the	predicted	
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molecular	 weight	 in	 RV1A-	iLOV–infected	 cells	 (Figure	2D),	 while	
viral	capsid	proteins	VP0	and	VP2	were	detected	in	both	RV1A-	and	
RV1A-	iLOV–infected	cells.






was	 stably	 retained	within	 the	RV	genome	over	 five	passages	 (P1	
to	P5)	 (Figure	3E).	Sequence	analysis	of	 the	 iLOV	 insert	confirmed	
these	results	and	revealed	no	mutations	(data	not	shown).
3.4 | Assessment of antiviral effects using RV1A- 
iLOV in vitro
We	 explored	 the	 application	 of	 RV1A-	ilOV	 to	 antiviral	 drug	
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infection.30	We	 infected	HeLa	 cells	 with	 RV1A-	iLOV	 at	 an	MOI	
of	0.1	for	24	hours	in	the	presence	of	different	concentrations	of	
bafilomycin.	iLOV	expression	was	examined	using	flow	cytometry	
(Figure	4A).	 Consistent	 with	 previous	 work,30	 bafilomycin	 com-
pletely	inhibited	iLOV	expression	at	a	concentration	of	0.1	μmol/L	













no	 statistical	difference	 in	viral	 load	between	RV1A-	iLOV	and	 the	
parental	RV1A	at	each	of	the	indicated	time	points	(Figure	5A).
Studies	 in	 coxsackievirus	 have	 shown	 that	 large	 insertions	 at	
the	analogous	capsid	protein	P-	1D	protease	2A	junction	may	delete	
readily.31,32	iLOV	stability	in	vivo	was	therefore	examined	by	RT-	PCR	
at	 each	 of	 the	 indicated	 time	 points	 (Figure	5B).	 The	 intact	 iLOV	
fragment	(~600-	bp	band)	along	with	a	size-	reduced	band	(~300	bp)	

















bleaching	of	 iLOV-	bound	 flavin	mononucleotide.	Similarly,	 imaging	
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imaging.	We	 infected	 mice	 with	 RV1A-	iLOV	 and	 harvested	 lungs	
one	day	postinfection.	We	have	previously	shown	that,	besides	air-
way	 epithelial	 cells,	 RV	 colocalizes	with	 CD68+	macrophages.13,14 
Immunohistochemical	staining	with	anti-	iLOV	showed	signal	in	both	
the	epithelium	and	macrophages	 (Figure	6A).	 Immunofluorescence	
similarly	 indicated	 localization	 in	 the	 airway	epithelium,	 as	well	 as	
colocalization	of	 iLOV	 (green)	with	VP2/0	 (red)	and	a	macrophage	
marker,	CD68	(blue,	Figure	6B).
We	 have	 previously	 shown	 that	 RV	 infection	 induces	 lung	
infiltration	 with	 CD11b-	positive,	 M2-	polarized	 exudative	 mac-
rophages.33	 For	 the	 analysis	 of	 intracellular	 iLOV,	 aliquots	 of	
lung	 mince	 were	 fixed,	 permeabilized,	 and	 incubated	 with	 the	
Cy3-	tagged	 anti-	iLOV	 prior	 to	 flow	 cytometry.	 Flow	 cytometric	
analysis	 showed	 similar	 increases	 in	 the	percentage	 for	CD45	+		
CD11b+	 cells	 in	 both	 RV1A-	 and	 RV1A-	iLOV–infected	 mice	
(Figure	6C),	 confirming	 the	 colocalization	 of	 lung	 macrophages	
and	RV.	However,	 a	 signal	was	detected	 in	CD45+	CD11b+	cells	
only	 in	 RV1A-	iLOV–infected	mice.	 Taken	 together,	 these	 results	





allowing	 tracking	of	viral	 infection	 in	vivo.	Using	 reverse	genetics,	
we	engineered	and	constructed	recombinant	RV1A	infectious	cDNA	





both	 in	 vitro	 and	 in	 vivo.	Evaluation	of	 iLOV	expression	was	used	
to	assess	the	antiviral	effects	of	bafilomycin	in	RV1A-	iLOV–infected	

















Construction	 of	 recombinant	 viruses	 expressing	 fluorescent	
markers,	 especially	GFP,	 has	 been	 applied	 through	 reverse	 genet-
ics	 to	 RNA	 viruses	 including	 influenza	 virus,34	 Zika	 virus,35	West	
Nile	virus,36	respiratory	syncytial	virus,37	murine	coronavirus,38 and 






















LOV	 (light,	 oxygen,	 or	 voltage	 sensing)	 domain	 offer	 advantages	
owing	to	their	smaller	size	(354	nt),	pH,	and	thermal	stability.43	iLOV	
was	created	from	the	LOV2	domain	of	the	phototropin	2	plant	blue	
light	 receptor	 of	Arabidopsis thaliana.26	 Unlike	GFP-	based	 fluores-














Similar	 to	 viral	 proteins,	 iLOV	 protein	 is	 released	 from	 the	 RV	








Because	 there	 are	more	 than	100	different	RV	 serotypes	 (in	
species	A	and	B	alone),	it	is	infeasible	to	develop	a	cross-	reactive	
antibody	for	RV.	Until	now,	only	one	antibody	has	been	available	
for	 this	 purpose,	 the	monoclonal	 antibody	 R16-	7.	 This	 antibody	
binds	to	the	VP2	capsid	protein	of	the	closely	related	RV-	A16	and	
RV-	A1	 strains6	 but	 not	 to	 RV-	A2,	 RV-	B14,	 or	 RV-	A49.15	We	 de-
veloped	a	recombinant	virus	with	a	fluorescent	marker	that	could	
be	 used	 for	 tracking	 of	 RV	 infection	 in	 vivo.	 We	 designed	 the	
iLOV	sequence	 to	be	 flanked	with	2Apro	 cleavage	sites	and	 then	




technique	 to	 all	 human	RVs.	Given	 the	 fact	 that	 iLOV	 sequence	
was	 stably	maintained	within	 RV1A	 genome	 during	 consecutive	
passages,	 it	 is	 plausible	 that	 other	 RVs	 serotypes	would	 accom-
modate	 and	 maintain	 the	 stability	 of	 iLOV	 sequence.	 Though	
the	 2Apro	 cleavage	 sites	 of	 numerous	 RV	 serotypes	 are	 hetero-
geneous,48	 designing	 the	 flanked	2Apro	 cleavage	 sequence	 to	be	
serotype-	specific	 would	 guarantee	 the	 release	 of	 iLOV.	 Besides	
VP1-	2A	 cleavage	 site,	 the	 junction	 site	 between	 5′UTR	 and	 the	
N-	terminus	of	VP4	has	been	used	to	insert	GFP	in	the	genome	of	
coxsackie	A16	virus49;	however,	 the	 insertion	 impaired	viral	 rep-
lication.	Taken	together,	these	data	suggest	that	the	construction	
strategy	 for	RV1A-	iLOV	could	be	 applied	 to	other	RV	 serotypes	
for	 studying	 the	 life	 cycle	 of	 RV	 in	 cultured	 cells,	 screening	 for	
antiviral	drugs	and	for	the	pathogenesis	of	RV.
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